Clinical trials: Self Harm
Major Depressive Disorder, Major Depressive Episode
The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition
This multi-site, double-blind, randomized, sham-controlled mechanistic trial aims to test the effects of Magnus Neuromodulation System (MNS) with Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) Technology on…
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
- Trial name
- SAINT®SC (NCT03693105)
- Testing
- Active SAINT Stimulation
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Magnus Medical
Depressive Disorder
Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of PEER Interactive to inform treatment in subjects with a primary diagnosis of depression with comorbidity of…
- Trial name
- NCT01794559
- Testing
- PEER Interactive Report
- Where
- 2 sites in United States
- Volunteers
- 1,922 people
- Sponsor
- MYnd Analytics
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Vitiligo, Depressive Episode
Mental Health Associations With Vitiligo
This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with…
- Conditions
- Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04953338
- Testing
- Exposure of mental health condtion of interest
- Where
- United Kingdom
- Volunteers
- 36,104 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Suicide, Suicidal
CAMPUS Expanded "Classification and Assessment of Mental Health Performance Using Semantics Expanded"
Open enrollment study to collect data for the optimization of machine learning models for use in an app for the early detection of mental health and suicidal risk.
- Conditions
- Suicide, Suicidal, Suicide, Attempted, Suicidal Ideation
- Trial name
- CAMPUS-E (NCT04493736)
- Testing
- MHSAFE app recording
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Clarigent Health
Depressive Disorder, Major, Suicidal Ideation
A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy
The purpose of the study is to describe the pharmacological and non-pharmacological treatment utilization pathways in Italian routine clinical practice of participants with Major Depressive Disorder (MDD) and active suicidal…
- Trial name
- ARIANNA (NCT04463108)
- Testing
- No Intervention
- Where
- 24 sites in Italy
- Volunteers
- 136 people
- Sponsor
- Janssen-Cilag S.p.A.
Depression, Insomnia
PracticeGround: Transforming Training and Delivery of Mental Health EBPs
The ultimate goal is to facilitate the delivery of empirically supported treatments (ESTs) for mental disorders and to improve client mental health outcomes.
- Conditions
- Depression, Insomnia, Suicide
- Trial name
- NCT02314624
- Testing
- Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality, Care-as-Usual Psychotherapy
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Bipolar Depression, Suicidal Ideation
NRX101 Glx Biomarker Validation Study
Subnormal level of Glutamate+Glutamine (Glx) in the Anterior Cingulate Cortex (ACC) of the brain has been associated with depression and PTSD.
- Trial name
- NRX-GLX (NCT03402152)
- Testing
- NRX-101, Lurasidone HCl
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NeuroRx, Inc.
Substance Use, Substance Abuse
Mobile Technology to Reduce Teen Substance Misuse
The goal of this study is to test the newly expanded WisePath for Teens (WPT) for substance use app, a direct-to-consumer paired mobile phone app for iOS and Android platforms that supports parents/guardians in delivering…
- Conditions
- Substance Use, Substance Abuse, Suicide, Adolescent
- Trial name
- NCT05897164
- Testing
- WisePath for Teens, Peer Support Services (PSS), Control
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Mental Health
An Evaluation of Innerview™, a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting
Innerview can address some of the challenges of integrating mental health and primary care by accurately and reliably collecting mental health evidence and activities directly from patients, and then organizing and automating…
- Trial name
- NCT02025647
- Where
- 5 sites in United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Pearson/Clinical Assessment
Major Depressive Disorder, Major Depressive Episode
SAINT for MDD in an Inpatient Setting Follow-on
Randomized, multi-site, sham-controlled, double-blinded study
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
- Trial name
- NCT06462820
- Testing
- Active SAINT Stimulation
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Magnus Medical
Child Behavior Disorders, Suicide and Self-harm
iKinnect2.0 for Juvenile Justice Involved Youth at Risk for Suicide
This study is a 16-week intent-to-treat randomized controlled trial (RCT) with 120 suicidal juvenile justice (JJ)-involved transition-age (TA) youth (age 15-21 years) and a primary caregiver (dyads).
- Trial name
- NCT04909203
- Testing
- iKinnect2.0, Active Control App
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Suicide, Attempted, Suicidal Ideation
Feasibility Study of a Software Application for Patients Hospitalized After Suicidal Ideation or Suicide Attempts
The primary objective of this feasibility study is to assess the feasibility, and usability of a software application to deliver targeted interactive exercises to patients recently hospitalized for suicidal ideation or suicide…
- Trial name
- NCT04295382
- Testing
- Software Application
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oui Therapeutics, Inc.
Suicide, Mental Health Disorder
A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- ViraSafeRCT (NCT07348666)
- Testing
- ViraSafe: Treatment pushes, BRITE
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ksana Health
Bipolar Depression, Suicidal Ideation
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of…
- Trial name
- SevereBD (NCT03396601)
- Testing
- Ketamine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- NeuroRx, Inc.
Depression, Suicide
Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults
The primary objective of the study is to estimate the incidence of suicide attempts resulting in a medical encounter or hospitalization in seven propensity matched cohorts of subjects: patients treated with duloxetine for…
- Trial name
- NCT00763724
- Volunteers
- 254,432 people
- Sponsor
- Eli Lilly and Company
Depression, Anxiety
Clairity in a University Mental Health Clinic
This is a clinical trial to evaluate the effectiveness of the Clairity tool within the university setting for students who are being seen by a mental health provider.
- Conditions
- Depression, Anxiety, Suicide, Mental Health Issue
- Trial name
- FECU (NCT05513963)
- Testing
- Clairity
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Clarigent Health
Depressive Disorder, Major, Suicidal
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in…
- Trial name
- NCT04669665
- Testing
- SLS-002, Standard of care, Intranasal device
- Where
- 21 sites in United States
- Volunteers
- 164 people
- Sponsor
- Seelos Therapeutics, Inc.
Bipolar Depression, Suicidal Ideas
Sequential Therapy for the Treatment of Severe Bipolar Depression.
NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or…
- Conditions
- Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
- Trial name
- STABIL-B (NCT02974010)
- Testing
- NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- NeuroRx, Inc.
Epilepsy
WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 and Workgroup 1.
- Trial name
- NCT01607333
- Testing
- Lamotrigine use
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline